Want to see IN:JUBLPHARMA full AI Analyst Report?

Jubilant Pharmova Limited (JUBLPHARMA) Price & Analysis

2 Followers

JUBLPHARMA Stock Chart & Stats

₹962.00

₹14.35(1.49%)

At close: Jul 27 4:00 PM EDT

₹962.00

₹14.35(1.49%)

Day’s Range― - ―

52-Week Range₹783.75 - ₹1,183.90

Previous CloseN/A

Volume117.87K

Average Volume (3M)17.59K

Market Cap

₹148.32B

Enterprise Value₹153.02B

Total Cash (Recent Filing)₹12.67B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)41.9

Beta0.84

Next Earnings

Oct 30, 2026

EPS Estimate

4.6

Next Dividend Ex-DateN/A

Dividend Yield0.54%

Share Statistics

EPS (TTM)22.24

Shares Outstanding159,281,140

10 Day Avg. Volume13,687

30 Day Avg. Volume17,585

Financial Highlights & Ratios

PEG Ratio-0.62

Price to Book (P/B)1.82

Price to Sales (P/S)1.56

P/FCF Ratio-29.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)40.5

Revenue Forecast (FY)₹93.55B

Bulls Say, Bears Say

Bulls Say

Diversified Life-sciences ModelServing customers across discovery, development, manufacturing, and commercialization gives the company multiple revenue avenues within life sciences. This breadth can support resilience across market cycles, diversify customer needs, and create opportunities to deepen relationships across the pharmaceutical value chain.

Steady Revenue GrowthA multi-year pattern of revenue expansion, with growth accelerating in FY2026, indicates continuing demand for the company’s products and services. Sustained top-line progress can improve operating scale, support investment in capabilities, and strengthen its position with global pharmaceutical customers.

Positive Operating Cash FlowPositive operating cash flow across the reported period shows that core operations generate cash, while growing equity provides a broader capital base. Together, these characteristics support ongoing investment and give the business some capacity to manage its development and manufacturing activities.

Bears Say

Volatile ProfitabilityLarge swings in profitability make earnings quality less predictable and weaken confidence that recent improvements will persist. The FY2026 margin decline also suggests that growth is not consistently converting into profits, which could constrain reinvestment and reduce resilience if conditions deteriorate.

Sharp Gross-margin DeclineThe sharp gross-margin reduction points to weaker mix or pricing, or higher input costs, and raises concern about the durability of earnings. Unless margins stabilize, additional revenue may deliver less operating benefit, limiting the company’s ability to compound profits from its expanding business base.

Unreliable Free Cash FlowRepeated negative free cash flow despite positive operating cash flow indicates that reinvestment or working-capital needs are absorbing available cash. Weak cash conversion can limit internally funded growth, increase reliance on financing, and make shareholder returns less dependable over the next several quarters.

Jubilant Pharmova Limited News

Jubilant Pharmova to Double RUBY-FILL Capacity with CAD 94.5 Million Québec Expansion

The latest announcement is out from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ). Jubilant Pharmova’s radiopharmaceutical arm, Jubilant Draximage...

4d ago

Jubilant Pharmova Opens Special Window for Physical Share Transfers and KYC Update

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has shared an update. Jubilant Pharmova has notified stock exchanges that it...

1M ago

Jubilant Pharmova Wins USFDA Nod for New Spokane Fill-and-Finish Line

An announcement from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) is now available. Jubilant Pharmova Limited announced that the...

2M ago

Jubilant Pharmova Publishes AGM, E-Voting and Dividend Notice

The latest announcement is out from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ). Jubilant Pharmova Limited operates in the...

2M ago

Jubilant Pharmova Updates Shareholders on AGM, Annual Report Access

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has provided an announcement. Jubilant Pharmova has informed exchanges that it has...

2M ago

Jubilant Pharmova Sets Final Dividend and Details TDS Rules for Shareholders

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an announcement. Jubilant Pharmova has informed shareholders that its board...

2M ago

Jubilant Pharmova Wins USFDA Tentative Nod for Pantoprazole Oral Suspension

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has provided an update. Jubilant Pharmova has announced that its subsidiary Jubilant...

4M ago

Jubilant Pharmova’s Spokane Plant Clears USFDA Inspection Without Sterility Issues

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has shared an announcement. Jubilant Pharmova Limited announced that the U.S. Food...

4M ago

Jubilant Pharmova Creates Canadian Arm to Build Branded Generics Business

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an update. Jubilant Pharmova’s step-down subsidiary, Jubilant Generics Limited, has...

10M ago

Jubilant Pharmova Subsidiary to Appeal Rs 9.71 Crore GST Demand, Sees No Material Impact

An update from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) is now available. Jubilant Pharmova has disclosed that its...

10M ago

JUBLPHARMA FAQ

What was Jubilant Pharmova Limited’s price range in the past 12 months?

Jubilant Pharmova Limited lowest stock price was ₹783.75 and its highest was ₹1183.90 in the past 12 months.

What is Jubilant Pharmova Limited’s market cap?

Jubilant Pharmova Limited’s market cap is ₹148.32B.

When is Jubilant Pharmova Limited’s upcoming earnings report date?

Jubilant Pharmova Limited’s upcoming earnings report date is Oct 30, 2026 which is in 18 days.

How were Jubilant Pharmova Limited’s earnings last quarter?

Jubilant Pharmova Limited released its earnings results on Aug 10, 2026. The company reported ₹3.5 earnings per share for the quarter, missing the consensus estimate of ₹5.8 by -₹2.3.

Is Jubilant Pharmova Limited overvalued?

According to Wall Street analysts Jubilant Pharmova Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Jubilant Pharmova Limited pay dividends?

Jubilant Pharmova Limited pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.54%. See more information on Jubilant Pharmova Limited dividends here

What is Jubilant Pharmova Limited’s EPS estimate?

Jubilant Pharmova Limited’s EPS estimate is 4.6.

How many shares outstanding does Jubilant Pharmova Limited have?

Jubilant Pharmova Limited has 159,281,140 shares outstanding.

What happened to Jubilant Pharmova Limited’s price movement after its last earnings report?

Jubilant Pharmova Limited reported an EPS of ₹3.5 in its last earnings report, missing expectations of ₹5.8. Following the earnings report the stock price went up 3.214%.

Which hedge fund is a major shareholder of Jubilant Pharmova Limited?

Currently, no hedge funds are holding shares in IN:JUBLPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Jubilant Pharmova Limited

Jubilant Pharmova Limited functions as a comprehensive pharmaceutical enterprise with a global footprint, structured into three primary divisions: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment is involved in a range of activities, including the production and distribution of allergy treatments, outsourced manufacturing of both sterile injectable and non-sterile medications, the creation of active pharmaceutical ingredients (APIs), and solid dose formulations. This division also markets radiopharmaceuticals through a network of 48 specialized pharmacies located across the United States. Its Contract Research & Development Services arm offers collaborative scientific investigation to pioneering pharmaceutical companies. Furthermore, the Proprietary Novel Drugs segment focuses on developing innovative therapies for conditions such as cancer and autoimmune diseases. Established in 1978 and headquartered in Noida, India, the company was formerly named Jubilant Life Sciences Limited before adopting its current designation, Jubilant Pharmova Limited, in February 2021.